

# Second-line nintedanib + docetaxel for patients with lung adenocarcinoma after failure on first-line immune checkpoint inhibitor combination therapy: initial efficacy and safety results from VARGADO Cohort C


Christian Grohé,<sup>1</sup> Thomas Wehler,<sup>2</sup> Tobias Dechow,<sup>3</sup> Sven Henschke,<sup>4</sup> Wolfgang Schütte,<sup>5</sup>  
Ina Dittrich,<sup>6</sup> Stefan Hammerschmidt,<sup>7</sup> Harald Müller-Huesmann,<sup>8</sup> Christian Schumann,<sup>9</sup>  
Stefan Krüger,<sup>10</sup> Judith Atz,<sup>11</sup> Rolf Kaiser<sup>11</sup>

<sup>1</sup>Department of Pneumology, ELK Berlin, Berlin, Germany; <sup>2</sup>EVK, Evangelisches Krankenhaus Hamm, Department of Hematology, Oncology, Pneumology and Palliative Medicine, Hamm, Germany; <sup>3</sup>Private Oncology Practice Ravensburg, Ravensburg, Germany; <sup>4</sup>Innere Medizin V, Medizinische Klinik, Universitätskliniken des Saarlandes, Homburg, Germany; <sup>5</sup>Martha-Maria City Hospital Halle-Doelau, Halle, Germany; <sup>6</sup>Lungenklinik Lostau, Lostau, Germany; <sup>7</sup>Department of Internal Medicine, Klinikum Chemnitz gGmbH, Chemnitz, Germany; <sup>8</sup>Klinik für Hämatologie und Onkologie, Bruederkrankenhaus St. Josef, Paderborn, Germany; <sup>9</sup>Clinic for Pneumology, Thoracic Oncology, Sleep- and Respiratory Critical Care, Kempten-Oberallgaeu Hospitals, Kempten, Germany; <sup>10</sup>Department of Pulmonology/Allergology/Sleep Medicine and Respiratory Care, Florence Nightingale Hospital, Düsseldorf, Germany; <sup>11</sup>Medical Affairs, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim Am Rhein, Germany.

# INTRODUCTION

- Treatment of advanced non-small cell lung cancer (NSCLC) has undergone significant changes, with immune checkpoint inhibitors (ICIs) alone, or in combination with chemotherapy, now the first-line standard of care for metastatic non-squamous NSCLC lacking an actionable driver mutation<sup>1</sup>
- For patients progressing on ICIs, only limited data are available on the efficacy of subsequent treatment sequences<sup>2-8</sup>
- Understanding the underlying tumor biology may help to guide treatment selection
- Excessive vascular endothelial growth factor (VEGF) can promote angiogenesis and create an immunosuppressive tumor microenvironment (TME) by modulating immune cell function and reducing immune cell access,<sup>7,9,10</sup> which likely contributes to ICI resistance and may potentially prime the tumor for anti-angiogenic therapy
- An anti-angiogenic treatment strategy involving inhibition of VEGF, platelet-derived growth factor (PDGF) and fibroblast growth factor (FGF), could support vessel normalization and improve immune cell access to the tumor, favoring the restoration of an immunosupportive TME in an 'angio-immunogenic switch' (**Figure 1**)

# Figure 1. A hypothesized 'angio-immunogenic switch'




# INTRODUCTION (CONT'D)

- Nintedanib is an oral, triple angiokinase inhibitor that targets VEGF receptors 1–3, PDGF receptors  $\alpha/\beta$ , FGF receptors 1–3, and RET<sup>11,12</sup>
- In the Phase III LUME-Lung 1 trial of patients with NSCLC who had progressed on first-line chemotherapy, nintedanib plus docetaxel significantly prolonged both progression-free survival (PFS) compared with placebo plus docetaxel, and overall survival (OS), in patients with adenocarcinoma NSCLC<sup>13</sup>
- This combination is approved in the European Union and other countries for the treatment of locally advanced, metastatic or locally recurrent adenocarcinoma NSCLC after first-line chemotherapy<sup>14</sup>
- The VARGADO study is being undertaken to assess the clinical utility of nintedanib plus docetaxel in a real-world setting, including patient cohorts who have progressed after prior chemotherapy and ICI therapy, to help inform clinical decision-making in the current ICI era<sup>15</sup>
- Here, we present the first analysis from Cohort C, the cohort of patients who received second-line nintedanib plus docetaxel after progression on first-line chemo-immunotherapy (chemo-ICI) treatment, as part of the non-interventional VARGADO study<sup>15</sup>

# STUDY DESIGN AND PATIENT POPULATION

- VARGADO (NCT02392455) is an ongoing prospective, non-interventional study of nintedanib plus docetaxel after first-line chemotherapy in the routine clinical treatment of patients with locally advanced, metastatic or locally recurrent adenocarcinoma NSCLC<sup>15</sup>
- Three patient cohorts are being evaluated (**Figure 2**)
- Between March 15, 2015 and April 6, 2021, 528 patients were enrolled in centers across Germany
- We present an initial analysis of Cohort C (n=100) (data cut-off: December 1, 2020)
- Nintedanib and docetaxel were administered according to the approved label
- Patients received docetaxel (75 mg/m<sup>2</sup>) by intravenous infusion on Day 1, plus oral nintedanib (200 mg twice daily) on Days 2–21 of each 21-day cycle
- Patients were followed for up for safety and efficacy for up to 24 months after the start of treatment. Patient data were collected during routine clinic visits
- The primary endpoint is the OS rate at 12 months after the start of treatment with nintedanib plus docetaxel. Secondary endpoints include PFS, OS, objective response rate (ORR), disease control rate (DCR) and safety
- Incidence and severity of adverse events (AEs) were reported according to National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.03

# Figure 2. Patient cohorts in VARGADO



Following protocol amendments:

- Inclusion of patients who received previous second-line ICI therapy was allowed (May 2016)
- Inclusion of patients who received previous first-line therapy with an ICI plus chemotherapy was allowed (September 2018)

FPI, first patient in; ICI, immune checkpoint inhibitor.

# RESULTS

## Patient characteristics

- This initial analysis includes the first 100 patients from Cohort C (second-line nintedanib plus docetaxel after failure of first-line chemo-ICI therapy)
- Clinical characteristics and previous treatments for patients in Cohort C are shown in **Tables 1 and 2**

**Table 1. Clinical characteristics for patients in Cohort C (n=100)**

Median age, years (range)		63 (43–84)
Sex, n (%)	Male	58 (58)
	Female	42 (42)
ECOG PS, n (%)	0	32 (32)
	1	39 (39)
	2	15 (15)
	3	2 (2)
	Not reported	12 (12)
Clinical stage at diagnosis, n (%)	≤III	20 (20)
	IV	75 (75)
	Not reported	5 (5)
Current or former smokers, n (%)		75 (75)
Presence of brain metastases, n (%)		17 (17)

## Table 2. Previous treatments for patients in Cohort C (n=100)

Previous first-line therapy, n (%)*	Pembro/pem/platinum	89 (89)
	Pembro/pem/carboplatin	68 (68)
	Pembro/pem/cisplatin	21 (21)
	Other pembro/chemo combination	6 (6)
	Atezo/pac/platinum	3 (3)
	Atezo/pac/carboplatin	1 (1)
	Atezo/pac/carboplatin/bevacizumab	2 (2)
	Nivolumab + chemotherapy	1 (1)
	Other	1 (1)
	Best response to first-line therapy, n (%) <sup>†</sup>	Complete response
Partial response		27 (27)
Stable disease		18 (18)
Progressive disease		27 (27)
Other		2 (2)
Time since start of first-line treatment	<9 months	66 (66)
	≥9 months	34 (34)


\*Percentage values refer to all patients (N=100); <sup>†</sup>Percentage based on patients with a documented response at the time of analysis. Atezo, atezolizumab; pac, paclitaxel; pem; pemetrexed; pembro, pembrolizumab.

# RESULTS (CONT'D)

## Efficacy

- We present initial efficacy data for patients in Cohort C (n=100) who received nintedanib plus docetaxel after first-line chemo-ICI
- At the time of this initial analysis (data cut-off: December 1, 2020), the median duration of follow-up was 5.3 months for patients treated with nintedanib plus docetaxel
- Fifty-one PFS events (disease progression or death) had occurred. For the PFS analysis, 49 patients had been censored
- Median PFS was 4.4 months (95% confidence interval [CI]: 2.6–6.6; n=100) (**Figure 3**)
- OS data are not yet mature and are not reported here

# Figure 3. PFS from the start of second-line nintedanib plus docetaxel after failure of chemo-ICI (n=100)



CI, confidence interval; PFS, progression-free survival.

# RESULTS (CONT'D)

## Efficacy (cont'd)


- At the time of analysis, best overall response data were available for 59 patients who received second-line nintedanib plus docetaxel after failure of chemo-ICI therapy (**Table 3**)
  - The ORR was 22/59 (37.3%)
  - The DCR was 40/59 (67.8%)
- The overall time on treatment (including first-line and second-line treatment) and best responses to nintedanib plus docetaxel (for patients with a documented response who received prior treatment with first-line pembrolizumab/pemetrexed/platinum-based regimens) are shown in **Figure 4**

**Table 3. Best response to second-line nintedanib plus docetaxel (n=59)\***

Objective response rate, n (%)	22 (37.3)
Complete response, n (%)	1 (1.7)
Partial response, n (%)	21 (35.6)
Stable disease, n (%)	18 (30.5)
Disease control rate, n (%)	40 (67.8)
Progressive disease, n (%)	18 (30.5)

\*One patient had a clinically documented response that was not clearly attributable to any category ('other' i.e. minimal remission). Data are for patients in the treated set who had a documented response.

# Figure 4. Swimmer plot showing overall time on treatment and best responses (n=51)\*



\*Data are for patients in the treated set who received prior treatment with first-line pembrolizumab/pemetrexed/platinum-based regimens and had a documented response to nintedanib plus docetaxel. †Minimal remission.

1L, first-line; 2L, second-line; CR, complete response; ICI, immune checkpoint inhibitor; PD, progressive disease; PR, partial response; SD, stable disease.

# RESULTS (CONT'D)

## Safety

- Safety was evaluated in all 100 patients treated with nintedanib plus docetaxel in Cohort C
- Seventy-eight (78%) patients had treatment-emergent AEs (TEAEs), with 55 (55%) experiencing drug-related AEs according to investigator assessment
- The most common drug-related AEs are shown in **Table 4**
- Grade  $\geq 3$  TEAEs occurred in 47 (47%) patients; serious TEAEs occurred in 37 (37%) patients
- Thirty-one (31%) patients had at least one nintedanib dose reduction, and 16 (16%) patients had at least one docetaxel dose reduction
- Investigator-defined drug-related TEAEs led to study-drug discontinuation in 16 (16%) patients
- There were no new safety signals or unexpected toxicities

**Table 4. TEAE by drug relationship reported in  $\geq 5\%$  of patients (n=100)\***

	Nintedanib related		Docetaxel related	
	All grades n (%)	Grade $\geq 3$ n (%)	All grades n (%)	Grade $\geq 3$ n (%)
Diarrhea	29 (29)	4 (4)	12 (12)	3 (3)
Nausea	13 (13)	0 (0)	17 (17)	0 (0)
Fatigue	12 (12)	0 (0)	15 (15)	0 (0)
Vomiting	6 (6)	0 (0)	5 (5)	0 (0)
WBC decreased	6 (6)	5 (5)	8 (8)	7 (7)
Decreased appetite	4 (4)	0 (0)	6 (6)	0 (0)
Alopecia	4 (4)	0 (0)	8 (8)	0 (0)

\*Data are for the treated set (all treated patients).

TEAE, treatment-emergent adverse event; WBC, white blood cell count.

# CONCLUSIONS

- Evaluating the best therapeutic sequence is key to understanding the underlying mechanism of resistance to ICIs, and to improve the long-term treatment of advanced NSCLC patients, but there is a lack of data to guide clinical decision-making post-ICI
- The initial data from VARGADO Cohort C provide the first evidence that second-line nintedanib plus docetaxel has clinically meaningful efficacy, and a manageable safety profile following progression on first-line chemo-ICI
- An 'angio-immunogenic switch' may be the mechanism underlying the efficacy of nintedanib plus docetaxel as anti-angiogenic therapy in this setting
- The results provide further evidence that can inform clinical decision-making and treatment sequencing by demonstrating the benefit of nintedanib as the triple angiokinase inhibitor after first-line chemo-ICI in the treatment of advanced adenocarcinoma NSCLC
- Recruitment and follow-up are ongoing for patients in this Cohort, and updated results will be presented at future congresses

# REFERENCES

1. Planchard D, et al. *Ann Oncol* 2018;29(Suppl. 4):iv192–iv237.
2. Reck M, et al. *Lung Cancer* 2020;148:159–65.
3. Corral J, et al. *Clin Transl Oncol* 2019;21:1270–9.
4. Grohé C, et al. *Ann Oncol* 2020;31:S875–76.
5. Molife C, et al. *Future Oncol* 2019;15:2915–31.
6. Shiono K, et al. *Thorac Cancer* 2019;10:775–81.
7. Popat S, et al. *Lung Cancer* 2020;144:76–84.
8. Harada D, et al. *Anticancer Res* 2019;39:4987–93.
9. Fukumura D, et al. *Nat Rev Clin Oncol* 2018;15:325–40.
10. van der Woude LL, et al. *Trends Cancer* 2017;3:797–808.
11. Hilberg F, et al. *J Pharmacol Exp Ther* 2018;364:494–503.
12. Hilberg F, et al. *Cancer Res* 2008;68:4774–82.
13. Reck M, et al. *Lancet Oncol* 2014;15:143–55.
14. Vargatef® Summary of Product Characteristics. [https://www.ema.europa.eu/en/documents/product-information/vargatef-epar-product-information\\_en.pdf](https://www.ema.europa.eu/en/documents/product-information/vargatef-epar-product-information_en.pdf) (Accessed: April 21, 2021).
15. Grohé C, et al. *Future Oncol* 2019;15:2699–706.

# ACKNOWLEDGEMENTS

**Disclosures:** The authors were fully responsible for all content and editorial decisions, were involved in all stages of poster development and have approved the final version. CG received honoraria from AstraZeneca, Boehringer Ingelheim, Lilly, MSD Oncology, Roche and Takeda; consulting/advisory fees from AstraZeneca, Boehringer Ingelheim and MSD Oncology; research funding from AstraZeneca; travel/accommodations expenses from Boehringer Ingelheim, Bristol-Myers Squibb and Roche. TW received consulting/advisory fees from AstraZeneca, Roche/Genentech, Pfizer, Bristol-Myers Squibb, AbbVie, Merck Serono and Boehringer Ingelheim; travel/accommodations expenses from Pfizer, Celgene, Roche/Genentech, Boehringer Ingelheim and AstraZeneca; honoraria from Roche/Genentech, Boehringer Ingelheim, Merck Sharp & Dohme and Bristol-Myers Squibb; research funding from AstraZeneca, Roche/Genentech and Boehringer Ingelheim. SH received consulting/advisory fees from Boehringer Ingelheim and Chugai Pharma; research funding from Amgen, AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Chugai Pharma, MSD, Novartis and Roche; travel/accommodations expenses from Amgen and Boehringer Ingelheim. WS received consulting/advisory fees and research funding from AstraZeneca, Roche, Boehringer Ingelheim and Bristol-Myers Squibb; research funding from Lilly, AbbVie, Merck, GlaxoSmithKline, Ose Pharma and Novartis; other relationships from AstraZeneca, Roche, Boehringer Ingelheim, Bristol-Myers Squibb and MSD. SH received honoraria, consulting/advisory fees and travel/accommodations expenses from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, MSD and Roche. HMM received honoraria, consulting/advisory and speaker's bureau fees and travel/accommodations expenses from Roche, Bristol-Myers Squibb, MSD, Janssen and Boehringer Ingelheim; honoraria, speaker's bureau fees and travel/accommodations expenses from Merck; expert testimony from Roche. CS received honoraria from AstraZeneca, Bristol-Myers Squibb, MSD Oncology and Pfizer. SK received honoraria from Boehringer Ingelheim. JA and RK are employees of Boehringer Ingelheim. ID, TD have no conflicts of interest to declare. During the preparation of this poster, medical writing assistance, supported financially by Boehringer Ingelheim, was provided by Syneos Health, UK.

**Disclaimer:** Copies of this poster are for personal use only and may not be reproduced without written permission from ASCO® and the authors. To download a copy of the poster, type the following URL into your browser: <https://www.inoncology.com/asco-2021-grohe-poster>

**Corresponding author:** Christian Grohé (Christian.Grohe@jsd.de).